Index Chapter 1: Introduction Page 4 1.1 Acute promyelocytic leukemia (APL) and therapy related APL (t-APL) Page 6 1.2 Therapy related acute myeloid leukemia Page 8 1.3 t-APL following multiple sclerosis and genetic variants of DNA double strand break repair genes Chapter 2: Mechanisms of the formation of t(15;17) in mitoxantrone related therapy related-APL following multiple sclerosis Page 14 ...

While it has been established that anti-phospholipid antibodies (aPL) are associated with recurrent miscarriage (RM), the importance of anti-beta2 glycoprotein 1 (GP1) IgG and anti-annexin V IgG antibodies as risk factors for RM is undefined. We have investigated the prevalence of anti-beta2 GP1 IgG and anti-annexin V IgG antibodies in 54 aPL-positive and 48 aPL-negative women with RM. The prev...

OBJECTIVE Antiphospholipid antibody (aPL) specificity for aPL-related events was evaluated in systemic lupus erythematosus (SLE). METHODS A study was carried out on 105 patients affected with SLE comparing the prevalence of lupus anticoagulant (LA) and IgG and IgM anticardiolipin antibodies (aCL) between patients with and without features of antiphospholipid syndrome (APS). Antiphospholipid a...

Background: Acute promyelocytic leukemia (APL) is a distinct subtype of myeloid (AML) with arrest in maturation cells series bone marrow. PML-RARA fusion resulting from t(15;17) translocation forms the genetic basis this haematological malignancy. Introduction specific differentiating targeted therapy i.e. All-trans retinoic acid (ATRA) have remarkably improved outcome previously dreaded AML. A...

BACKGROUND Antiphospholipid antibodies (aPL) are a heterogeneous family of antibodies associated with thrombosis and other complications. OBJECTIVE To study the prevalence of aPL in patients with thrombosis at Aleppo University Hospitals, Syria. METHODS One hundred and fifty-seven patients with venous and arterial thrombosis and 63 healthy controls were studied. Anticardiolipin antibodies (...

BACKGROUND There are very limited prospective data on the significance of persistent antiphospholipid antibodies (aPL) and recurrent thrombo-occlusive events (TOEs). We investigated the prognostic value of (1) 2 newer aPL assays, (2) an aPL portfolio and (3) persistent aPL positivity following stroke. METHODS A total of 1,770 subjects from the APASS-WARSS study underwent further aPL testing f...

The adapter protein metastasis suppressor 1 (MTSS1) is implicated as a tumor suppressor or tumor promoter, depending on the type of solid cancer. Here, we identified Mtss1 expression to be increased in AML subsets with favorable outcome, while suppressed in high risk AML patients. High expression of MTSS1 predicted better clinical outcome of patients with normal-karyotype AML. Mechanistically, ...

BACKGROUND/AIMS Antiphospholipid antibodies (aPL) have been detected in various proportions of patients with primary immune thrombocytopenia (ITP), but the clinical significance of this is debatable. The present study aimed to determine the frequency and clinical implications of elevated aPL in adult patients with ITP. METHODS We prospectively studied newly diagnosed adult patients with ITP w...

Oral potassium arsenite used to be an important antileukemic agent1 until the 1950s, when it was surpassed by modern chemotherapeutic drugs. The use of arsenic resurged when its high efficacy was shown in acute promyelocytic leukemia (APL).2,3 However, to date, only intravenous As2O3 has been used. We have recently redeveloped an oral preparation of As2O3, which achieved total blood cell and pl...